Vanda Pharmaceuticals (VNDA) Profit After Tax (2010 - 2026)

Vanda Pharmaceuticals has disclosed Profit After Tax across 17 years of filings, most recently posting -$48.6 million for Q1 2026.

• Profit After Tax for Q1 2026 came in at -$48.6 million, down 64.67% year-over-year; the trailing twelve-month figure through Mar 2026 was -$239.5 million (down 441.37% YoY), and the FY2025 annual result was -$220.5 million, down 1066.53% from the prior year.
• Profit After Tax came in at -$48.6 million for Q1 2026 at Vanda Pharmaceuticals, up from -$141.2 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of $6.9 million in Q4 2022 to a low of -$141.2 million in Q4 2025.
• The 5-year median for Profit After Tax is -$4.5 million (2024), against an average of -$16.4 million.
• Across the five-year window, Profit After Tax surged 150.58% in 2023 and sank 3986.13% in 2024, its largest moves.
• Vanda Pharmaceuticals' Profit After Tax stood at $6.9 million in 2022, then sank by 134.98% to -$2.4 million in 2023, then tumbled by 104.67% to -$4.9 million in 2024, then plunged by 2774.33% to -$141.2 million in 2025, then jumped by 65.6% to -$48.6 million in 2026.
• The last three Profit After Tax figures came in at -$48.6 million (Q1 2026), -$141.2 million (Q4 2025), and -$22.6 million (Q3 2025), per Business Quant data.